Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:41 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 184,974 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NOT program Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

NCT01376726
View directory record Official record
Conditions
HIV Infections
Interventions
Sub C gp140 Vaccine, MF59C.1 Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Nov 2, 2026, 9:41 PM EST
Terminated Phase 2 Interventional Results available

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

NCT04538378
View directory record Official record
Conditions
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions
Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 2, 2026, 9:41 PM EST
Terminated No phase listed Observational

Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence

NCT03108885
View directory record Official record
Conditions
Esophageal Neoplasm, Esophageal Neoplasms Malignancy Unspecified, Esophageal Neoplasms Malignant, Cancer of Esophagus, Cancer of the Esophagus, Esophageal Cancer, Esophagus Cancer, Neoplasm, Esophageal
Interventions
Blood and Tissue Collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Nov 2, 2026, 9:41 PM EST
Terminated Not applicable Interventional Results available

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
Drug
Lead sponsor
Lehigh Valley Hospital
Other
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 2, 2026, 9:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

TAPS-ESP: Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use Electronic Spanish Platform

NCT03879785
View directory record Official record
Conditions
Tobacco, Alcohol, Prescription Drug, and Illicit Substance Use
Interventions
Screening
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 4 Interventional Results available

Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

NCT02964585
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Parents Matter!: Interventions to Promote Effective Parent-Child Communication

NCT00137943
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Pregnancy
Interventions
Full Parent communication intervention, Brief Parent Communication Intervention, Control Parent Intervention
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
9 Years to 12 Years
Enrollment
2,210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
3
States / cities
Little Rock, Arkansas • Athens, Georgia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Nov 2, 2026, 9:41 PM EST
Terminated Phase 3 Interventional

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

NCT02562443
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts, RAEB
Interventions
rigosertib, Any approved or standard-of-care therapy, best supportive care (BSC)
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 81 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Fleming Island, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Nov 2, 2026, 9:41 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Comparative Effects of Two Anesthetic Techniques on Auditory Brain Response in Children

NCT02830815
View directory record Official record
Conditions
Auditory Brainstem Response
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 1 Interventional

Chlorpromazine and Standard of Care in Glioblastoma

NCT05190315
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Chlorpromazine, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 2, 2026, 9:41 PM EST
Completed No phase listed Observational

Optimizing GWG in Obese Pregnant Women: A Nationwide Real-World Study Using the U.S. Natality Cohort

NCT07796815
View directory record Official record
Conditions
Pregnancy in Obesity, Gestational Weight Gain
Interventions
Gestational Weight Gain
Behavioral
Lead sponsor
Shanghai First Maternal and Infant Health Hospital affiliated to Tongji University Medical School
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,600,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 2, 2026, 9:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers

NCT05134415
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
RELX ENDS Tobacco Flavor 1, RELX ENDS Tobacco Flavor 2, RELX ENDS Menthol Flavor 1, RELX ENDS Menthol Flavor 2
Other
Lead sponsor
Cheerain HK Limited
Industry
Eligibility
22 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Burbank, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

NCT04800315
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
CC-93538, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
62
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 4 Interventional Results available

Pilot Study for Patients With Poor Response to Deferasirox

NCT00749515
View directory record Official record
Conditions
Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions
Deferoxamine, Deferasirox, HIDA
Drug · Radiation
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Nov 2, 2026, 9:41 PM EST
Not listed Phase 1Phase 2 Interventional

Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

NCT00184015
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
Bevacizumab and Bortezomib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Nov 2, 2026, 9:41 PM EST
Recruiting Phase 4 Interventional

Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

NCT07816835
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Nebulized therapy of similar medication solutions, Continue handheld therapy
Device
Lead sponsor
COPD Foundation
Other
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Saint Charles, Missouri • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 2, 2026, 9:41 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Autism Biomarker Consortium for Clinical Trials (ABC-CT): Follow-up Study

NCT04841525
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
6 Years to 11 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Nov 2, 2026, 9:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Radiofrequency and Ultrasound for Improvement of Skin Laxity and Wrinkles: Efficacy and Safety Evaluation

NCT05929625
View directory record Official record
Conditions
Skin Laxity
Interventions
BTL-585-2 RF+US, BTL-585-2 RF
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Birmingham, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 2, 2026, 9:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Behavioral Smoking Cessation Treatment - 1

NCT00110825
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Cognitive Behavior Therapy
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Nov 2, 2026, 9:41 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes

NCT02313376
View directory record Official record
Conditions
Malaria
Interventions
GAP3KO
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Nov 2, 2026, 9:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Pain Avoidance Behavior and Its Relation to Risk for Opioid Use in Chronic Pain Patients

NCT04603417
View directory record Official record
Conditions
Chronic Pain, Opioid Use
Interventions
Electroencephalography (EEG)/Magnetoencephalography (MEG)/MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Nov 2, 2026, 9:41 PM EST
Completed Early Phase 1 Interventional

RANKL Inhibition and Breast Tissue Biomarkers

NCT03629717
View directory record Official record
Conditions
Breast Cancer Prevention, Mammographic Density
Interventions
Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D
Procedure · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
35 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Nov 2, 2026, 9:41 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NCT00462917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure, AD-only info, phone disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Nov 2, 2026, 9:41 PM EST